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Abstract   46 
Psychostimulant addiction is a heritable substance use disorder; however its genetic basis is 47 
almost entirely unknown. Quantitative trait locus (QTL) mapping in mice offers a complementary 48 
approach to human genome-wide association studies and can facilitate environment control, 49 
statistical power, novel gene discovery, and neurobiological mechanisms. We used interval-50 
specific congenic mouse lines carrying various segments of chromosome 11 from the DBA/2J 51 
strain on an isogenic C57BL/6J background to positionally clone a 206 kb QTL (50,185,512-52 
50,391,845 bp) that was causally associated with a reduction in the locomotor stimulant 53 
response to methamphetamine (2 mg/kg, i.p.; DBA/2J < C57BL/6J) - a non-contingent, drug-54 
induced behavior that is associated with stimulation of the dopaminergic reward circuitry. This 55 
chromosomal region contained only two protein coding genes - heterogeneous nuclear 56 
ribonucleoprotein, H1 (Hnrnph1) and RUN and FYVE domain-containing 1 (Rufy1). 57 
Transcriptome analysis via mRNA sequencing in the striatum implicated a neurobiological 58 
mechanism involving a reduction in mesolimbic innervation and striatal neurotransmission. For 59 
instance, Nr4a2 (nuclear receptor subfamily 4, group A, member 2), a transcription factor crucial 60 
for midbrain dopaminergic neuron development, exhibited a 2.1-fold decrease in expression 61 
(DBA/2J < C57BL/6J; p 4.2 x 10 -15). Transcription activator-like effector nucleases (TALENs)-62 
mediated introduction of frameshift deletions in the first coding exon of Hnrnph1, but not Rufy1, 63 
recapitulated the reduced methamphetamine behavioral response, thus identifying Hnrnph1 as 64 
a quantitative trait gene for methamphetamine sensitivity. These results define a novel 65 
contribution of Hnrnph1 to neurobehavioral dysfunction associated with dopaminergic 66 
neurotransmission. These findings could have implications for understanding the genetic basis 67 
of methamphetamine addiction in humans and the development of novel therapeutics for 68 
prevention and treatment of substance abuse and possibly other psychiatric disorders. 69 
70 
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Author Summary  71 
Both genetic and environmental factors can powerfully modulate susceptibility to 72 
substance use disorders. Quantitative trait locus (QTL) mapping is an unbiased discovery-73 
based approach that is used to identify novel genetic factors and provide new mechanistic 74 
insight into phenotypic variation associated with disease. In this study, we focused on the 75 
genetic basis of variation in sensitivity to the acute locomotor stimulant response to 76 
methamphetamine which is a behavioral phenotype in rodents that is associated with stimulated 77 
dopamine release and activation of the brain reward circuitry involved in addiction. Using brute 78 
force monitoring of recombination events associated with changes in behavior, we fortuitously 79 
narrowed the genotype-phenotype association down to just two genes that we subsequently 80 
targeted using a contemporary genome editing approach. The gene that we validated – 81 
Hnrnph1 – is an RNA binding protein that did not have any previously known function in 82 
psychostimulant behavior or psychostimulant addiction. Our behavioral data combined with our 83 
gene expression results provide a compelling rationale for a new line of investigation regarding 84 
Hnrnph1 and its role in neural development and plasticity associated with the addictions and 85 
perhaps other dopamine-dependent psychiatric disorders.  86 
 87 
88 
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Introduction 89 
Substance use disorders (SUDs) involving psychostimulants such as cocaine and 90 
methamphetamine (MA) are heritable; however, their major genetic determinants remain poorly 91 
defined [1-4]. In particular, genome-wide association studies (GWAS) of psychostimulant abuse 92 
have yet to discover the underlying genetic factors or causal sequence variants. SUDs involve 93 
multiple discrete steps including initial use, escalation, withdrawal, and relapse, each of which is 94 
believed to have a distinct genetic architecture. Therefore, we and others have used model 95 
organisms to explore the genetic basis of intermediate phenotypes, including initial drug 96 
sensitivity [5]. Model systems have great potential for studying addiction-relevant intermediate 97 
phenotypes [6] because they provide exquisite control over environmental conditions, including 98 
exposure to psychostimulants.  99 
 Psychostimulants activate the mesocorticolimbic reward circuitry in humans [7] and 100 
stimulate locomotor activity in mice [8]. The primary molecular targets of psychostimulants are 101 
the membrane-spanning monoaminergic transporters. Amphetamines act as substrates and 102 
cause reverse transport and synaptic efflux of dopamine, norepinephrine, and serotonin [9-11]. 103 
Sensitivity to the locomotor stimulant response to MA is heritable and may share a genetic basis 104 
with the addictive, neurotoxic, and therapeutic properties of amphetamines [8, 12-15]. More 105 
broadly, determining the genetic basis of sensitivity to amphetamines may provide insight into 106 
the neurobiology of other conditions involving perturbations in dopaminergic signaling, including 107 
attention deficit hyperactive disorder (ADHD), schizophrenia, and Parkinson’s disease [16]. This 108 
hypothesis is supported by our recent identification of a genetic correlation between alleles that 109 
increased amphetamine-induced euphoria and alleles that decreased risk of schizophrenia and 110 
ADHD [17].  111 
We and others have reported several quantitative trait loci (QTLs) in mice that influence 112 
MA sensitivity [12, 18-24]. A distinct advantage of QTL analysis is that chromosomal regions 113 
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can eventually be mapped to their causal polymorphisms. However, obtaining gene-level and 114 
nucleotide-level resolution can be extremely challenging when beginning with a lowly 115 
recombinant population such as an F2 cross. A classical approach is to fine map QTLs derived 116 
from an F2 cross using successively smaller congenic strains. Whereas this approach is efficient 117 
for Mendelian alleles, there are only a few examples in which this approach has been 118 
successful in identifying alleles for more complex, polygenic traits, such as histocompatibility 119 
[25], substance abuse [26] and depressive-like behavior [27].    120 
In the present study, we fine mapped a QTL on chromosome 11 that modulates 121 
methamphetamine sensitivity and that segregates between C57BL/6J (B6) and DBA/2J (D2) 122 
inbred strains [12, 20]. We used interval-specific congenic lines in which successively smaller 123 
D2-derived segments were introgressed onto a B6 background [28]. We also conducted 124 
transcriptome analysis of brain tissue from a congenic line that captured the QTL for reduced 125 
MA sensitivity. Our transcriptome analysis focused on the striatum, which is a brain region 126 
important for psychostimulant-induced locomotor activity and reward [29]. We used 127 
GeneNetwork [30] and in silico expression QTL (eQTL) analysis of several brain regions to 128 
identify cis- and trans-eQTLs that may explain changes in the transcriptome caused by this 129 
QTL. Finally, to identify the quantitative trait gene responsible for reduced MA sensitivity, we 130 
used transcription activator-like effector nucleases (TALENs) to introduce frameshift deletions in 131 
the first coding exon of each positional candidate gene [31].    132 
 133 
Results 134 
Identification of a 206 kb critical interval for reduced MA sensitivity 135 
 Several genome-wide significant QTLs that influenced MA sensitivity were previously 136 
reported in this B6 x D2-F2 cross, including QTLs on chromosomes 1, 8, 9, 11, 15, and 16 [20]. 137 
Here, we further dissected the chromosome 11 QTL (peak = 50 Mb; D2 < B6) into 5 min bins 138 
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and identified a peak LOD score at 25 min post-MA administration (Fig. 1). We then produced 139 
interval-specific congenic lines to fine map this QTL. The genomic intervals (Mb) for the 140 
congenic lines and the peak F2-derived QTL are illustrated in Figure 2a and the SNP markers 141 
that defined the congenic intervals for Lines 1-6 are listed in Table S1. As shown in Figures 2b-142 
e, some of the congenic lines captured a QTL that reduced MA sensitivity whereas others did 143 
not (see also Fig. S2a, S2b). Whether or not a strain captured a QTL is indicated by a + or – 144 
sign in Figure 2a.   145 
Congenic Line 4 was the smallest congenic that captured a QTL for reduced MA 146 
sensitivity. Therefore, we produced subcongenic lines from Line 4, as shown in Figure 3a. The 147 
SNP markers that defined the congenic intervals for Lines 4a-4h are listed in Table S2. 148 
Production and analysis of these congenic lines was more efficient because the D2-derived 149 
allele was dominant. Therefore all lines shown in Figure 3 were heterozygous for the D2-derived 150 
congenic interval. Once again, some but not all of the congenic lines captured the QTL inherited 151 
from Line 4 (Figure 3b-d; Fig. S3; Table S3). Based on the observation that Line 4b but not 4c 152 
captured the QTL, we were able to define a 206 kb critical interval (Figure 3e). The first proximal 153 
SNP in Lines 4b was rs29424921 and first proximal SNP in Line 4c was rs29442500. The 154 
physical location of these SNPs defined the boundaries of the critical interval (50,185,512-155 
50,391,845 bp; Table S2). This interval contains only two protein coding genes: Hnrnph1 156 
(heterogeneous nuclear ribonucleoprotein) and Rufy1 (RUN and FYVE domain containing 1; 157 
Figure 3e; Table S4).   158 
Using Line 4c to define the distal boundary presumes that our analysis of Line 4c was 159 
powerful enough to detect the QTL if it were present. We used data generated from Line 4b to 160 
estimate the QTL effect size; based on this estimate, a sample size of N = 25 per group would 161 
be required to achieve 80% power to detect this QTL in Line 4c. We phenotyped an even larger 162 
number of mice from Line 4c (N = 30-40 per genotype), but did not detect the QTL (Fig. 3d). 163 
Therefore, we can confidently interpret the negative results from Line 4c. Further negative 164 
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results obtained from five additional subcongenic lines also support the critical interval as 165 
defined in Figure 3e (see Fig. S3; Table S3). 166 
Residual heterozygosity 167 
 Studies of congenic lines can be confounded by residual heterozygosity that lies 168 
outside of the congenic region. In order to address this concern, we genotyped individuals from 169 
Line 4 subcongenics at 882 SNPs using a SNP genotyping microarray. Although we did identify 170 
a single D2-derived SNP on chromosome 3, it was observed both in wild-type and heterozygous 171 
congenic mice and was not associated with the locomotor response to MA (see Fig. S4). Based 172 
on these results we rejected the possibility that the differences in the congenic lines were due to 173 
residual heterozygosity. 174 
Transcriptome of Line 4a 175 
In an effort to understand the molecular impact of this QTL, we used RNA-seq to identify 176 
gene expression differences in the striatum of naïve Line 4a congenics versus their naïve B6 177 
littermates. We identified between 91 differentially expressed genes with an FDR of 5% and 174 178 
differentially expressed genes with and FDR of 20%. The majority of these genes were 179 
downregulated in Line 4a (Table S6). Notably, Nr4a2 (Nurr1) was the most significant, 180 
demonstrating a 2.1-fold decrease in expression (p = 4.2 x 10-15; Figure 4). Decreased Nurr1 181 
expression in Line 4a was confirmed using qPCR (Fig. S5a; Table S7).  182 
We used the Ingenuity Pathway Analysis (IPA; Ingenuity® Systems, Redwood City, CA, 183 
USA; www.qiagen.com/ingenuity) software in conjunction with the genes we identified with an 184 
FDR of 5% to explore pathways that were enriched for these genes. The top three canonical 185 
pathways that we identified included the neuronal functions Glutamate Receptor Signaling, Gαq 186 
Signaling, and G-Protein Coupled Receptor Signaling (Table S8). Neither transcriptome nor 187 
qPCR analysis detected any significant difference in gene- or exon-level expression of Hnrnph1 188 
or Rufy1 (Fig. S5b, S5c; Fig. S6). The most strongly implicated IPA network was, “Cellular 189 
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Development, Nervous System Development and Function, Behavior”. This network consists of 190 
several downregulated genes involved in neural development, maintenance, and signaling (Fig. 191 
4), including Bdnf, which was downregulated and connected to several downregulated genes 192 
involved in synaptic transmission, including Malat1, the vesicular glutamate transporters 193 
VGLUT1 (Slc17a7) and VGLUT2 (Slc17a6), as well as the AMPA-4 receptor subunit (Gria4), 194 
alpha-1d adrenergic receptor (Adra1d), and calcium-dependent secretion activator 2 (Cadps2). 195 
The top “Diseases and Functions” annotations included Huntington’s disease, nervous system 196 
coordination, and disorder of basal ganglia (Table S9), further supporting dysfunction in striatal 197 
innervation and signaling. Htt (huntingtin) was the top predicted upstream transcriptional 198 
regulator followed by Creb1 (cyclic AMP response element binding protein) which together 199 
accounted for 23 (25%) of the 91 differentially expressed genes (Fig. S7).  200 
Gene Ontology (GO) pathways identified via WebGestalt [32, 33] complemented the IPA 201 
results and generally indicate neuronal dysfunction. The top biological process was synaptic 202 
transmission and signaling processes, the top molecular functions involved membrane proteins 203 
including transporters and g protein-coupled receptors and the top cellular components were 204 
associated with neuronal synapses (Table 1).  205 
eQTLs associated with differentially expressed genes in Line 4a 206 
 In order to identify genetic polymorphisms associated with changes in gene expression 207 
observed in the congenic region of Line 4a, we used GeneNetwork [30] to identify both cis- and 208 
trans-eQTLs that originated from B6/D2 polymorphisms within the Line 4a congenic region 209 
(FDR < 20%; Table S6). We identified several trans-QTLs caused by SNPs within the Line 4a 210 
region, including a link between genetic variation in Hnrnph1 and differential expression of 211 
Ipcef1 (Table 2; Table S6) [30], a gene that lies within Oprm1 (mu opioid receptor) and is 212 
transcribed in the reverse direction. These observations support the gene expression 213 
differences we observed using RNA-seq and indicate that our QTL regulates the expression of 214 
numerous other genes outside of the QTL interval.  215 
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Recapitulation of the congenic QTL phenotype in mice heterozygous for a 216 
frameshift deletion in Hnrnph1, but not Rufy1 217 
 One of the major advantages of genetic analysis in model organisms is the ability to 218 
perform experimental manipulations to evaluate observed correlations between genotype and 219 
phenotype. We used TALENs to introduce frameshift deletions that resulted in premature stop 220 
codons into the first coding exon of each of the two protein coding genes within the 206 kb 221 
critical interval – Hnrnph1 and Rufy1. We identified two founders that were heterozygous for 11 222 
bp and 16 bp frameshift deletions in the first coding exon of Hnrnph1 (Hnrnph1 +/-; Founders #28 223 
and #22; Fig. 5a; Fig. S8). We did not observe any off-target deletions in the highly homologous 224 
Hnrnph2 gene nor did we observe compensatory change in striatal Hnrnph2 expression (Figure 225 
S9). 226 
 Hnrnph1 +/- mice showed reduced expression of Hnrnph1. When we used qPCR 227 
primers that hybridized to DNA sequences that were contained in both wild-type (Hnrnph1 +/+) 228 
and Hnrnph1 +/- mice, there was a significant upregulation of total Hnrnph1 transcript levels in 229 
Hnrnph1 +/- versus Hnrnph1 +/+ mice (Fig. 5c, d). However, we also used qPCR primers that 230 
overlapped the deleted interval and in this case we observed a significant downregulation of 231 
Hnrnph1 +/+ transcript levels in Hnrnph1 +/- mice (Fig. 5e). These observations provide functional 232 
evidence that the Hnrnph1 frameshift deletion disrupted gene transcription. Similar to Lines 4, 233 
4a and 4b, Hnrnph1 +/- mice from Line #28 and Line #22 that were derived from Founders #28 234 
and #22 both exhibited reduced MA sensitivity (Fig. 5f, g), thus recapitulating the congenic QTL 235 
phenotype. Reduced MA sensitivity was also observed using 30 min behavioral sessions (Fig. 236 
S10).  237 
 In contrast to Hnrnph1 +/- mice, Rufy1 +/- mice carrying a frameshift deletion (Fig. S8) 238 
did not exhibit any difference in behavior (Fig. 6). To further support the likelihood of reduced 239 
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neurobehavioral function in Hnrnph1 +/- mice, Hnrnph1 expression is also clearly higher than 240 
Rufy1 in the adult brain (Figs. S6, S11 [34]).  241 
 To summarize, we observed a significant reduction in MA sensitivity in Hnrnph1 +/- 242 
mice, but not Rufy1 +/- mice that recapitulated the congenic QTL phenotype, thus identifying 243 
Hnrnph1 as a quantitative trait gene for MA sensitivity. 244 
 245 
Discussion 246 
We used positional cloning and gene targeting to identify Hnrnph1 as a novel 247 
quantitative trait gene for MA sensitivity. First, we identified a broad, time-dependent QTL on 248 
chromosome 11 using an F2 cross between two inbred strains (Fig. 1). We then narrowed a QTL 249 
from the initial 40 Mb interval to approximately 10 Mb using interval-specific congenic lines 250 
(Figs. 2, 3; Figs. S2, S3). Further backcrossing yielded a fortuitous recombination event that 251 
narrowed a critical interval to just 206 Kb; this region contained only two protein coding genes: 252 
Hnrnph1 and Rufy1 (Fig. 3e). Striatal transcriptome analysis identified potential neurobiological 253 
mechanisms, including a predicted deficit in midbrain dopaminergic neuron development and 254 
neurotransmission. The use of GeneNetwork [30] to identify eQTLs associated with our 255 
transcriptomic findings provided mechanistic insight, including a trans-QTL that maps to 256 
Hnrnph1 that could cause differential expression of Ipcef1 (Table 2; Table S6). Finally, we took 257 
advantage of the power of mouse genetics to create mice heterozygous for a frameshift deletion 258 
in either Hnrnph1 or Rufy1. Hnrnph1 +/- mice but not Rufy1 +/- mice recapitulated the congenic 259 
QTL phenotype, providing direct evidence that Hnrnph1 is a quantitative trait gene for MA 260 
sensitivity (Figs. 5-6).  261 
QTL mapping studies of rodent behavior have rarely provided strong evidence for causal 262 
quantitative trait genes [26, 27, 35]. We began pursuing this QTL more than a decade ago, 263 
when the difficulty of such projects was widely underestimated. A key limitation of our initial 264 
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mapping strategy was the use of an F2 cross, in which extensive linkage disequilibrium created 265 
large haplotype blocks, resulting in the identification of very broad QTLs. Combining low 266 
resolution and high resolution QTL mapping in congenic lines revealed a more complex genetic 267 
architecture, indicating that Hnrnph1 is not the only causal gene within the F2 interval that 268 
underlies the QTL. Inheritance of two copies of the D2 segment enhanced the heterozygous 269 
phenotype in Line 1, yet had no further effect once the size of the segment was reduced 270 
following the creation of Line 4 (Fig. 2b, e). We interpret this observation to suggest that Line 1 271 
contains an additional, recessive QTL within the 35-50 Mb region of Line 3 that could summate 272 
with the Line 4 QTL to produce the larger effect size. This 35-50 Mb region could be fine-273 
mapped to the causal genetic factor by introducing additional recombination events into Line 3. 274 
This detailed level of insight into the genetic architecture of a single large-effect QTL could only 275 
be made possible by employing a sufficiently powered phenotypic analysis of interval-specific 276 
congenic lines. Thus, a key to our success in identifying a single gene was the fact that while 277 
the QTL originally identified in the F2 cross was likely the product of multiple smaller QTLs, we 278 
were able to capture one major QTL in Line 4 and in subcongenic lines which appears to 279 
correspond to a single quantitative trait gene that we have now identified as Hnrnph1.  280 
Transcriptome analysis of Line 4a supports a neurodevelopmental mechanism by which 281 
the QTL regulates MA sensitivity. Nr4a2 (a.k.a. Nurr1) was the top downregulated gene and 282 
codes for a transcription factor that is crucial for midbrain dopaminergic neuron development, 283 
survival, and cellular maintenance of the synthesis, packaging, transport, and reuptake of 284 
dopamine [36]. Nurr1 was a core component of a top-ranked gene network composed of 285 
primarily downregulated genes important for neurogenesis, neural differentiation, and 286 
synaptogenesis (Nr4a2 / Nurr1, Bdnf, Tbr1, Neurod6, Ets2, Malat1, Elavl2; Fig. 4). Accordingly, 287 
there was a downregulation of striatal signaling pathways, including glutamate (Slc17a7, 288 
Slc17a6, Gng2, and Gria4), Gαq (Gng2, Chrm1, Adra1b, Adra1d), and GPCR signaling (Pde1b, 289 
Rgs14, Chrm1, Adra1b, Adra1d) (Table S8). With regard to Gαq signaling, MA acts as a 290 
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substrate for NET, causing efflux of NE [9] which then binds to α-adrenergic receptors that are 291 
coded by Adra1b and Adra1d. Notably, knockout mice for either of these receptors exhibit 292 
reduced amphetamine-induced locomotor activity [37, 38].  293 
Some of the differentially expressed genes in Line 4a were previously associated with 294 
variation in amphetamine reward and reinforcement, including Nr4a2 (Nurr1), Adora2a, and 295 
Slc17a7 (Vglut1) [39]. Furthermore, the top predicted upstream regulator - Htt (huntingtin; Fig. 296 
S7a) is a master regulator of a network of genes in the extended amygdala associated with 297 
protracted abstinence from chronic exposure to opioids, cannabinoids, nicotine, and alcohol 298 
[40].  299 
Inheritance of the Hnrnph1 locus caused downregulation of a smaller reverse-300 
transcribed gene located within the middle of Oprm1 (mu opioid receptor) called Ipcef1 (p = 301 
0.001; FDR = 12%; Table S6). We also identified a trans-eQTL in Hnrnph1 that regulates Ipcef1 302 
expression (Table 2 [30]). Hnrnph1 was previously shown to regulate the expression Oprm1 303 
(mu opioid receptor gene) via 5’ UTR-mediated repression [41]  and splicing [42]. Furthermore, 304 
the human intronic SNP rs9479757 in OPRM1 was associated with heroin addiction severity 305 
and decreased binding affinity of HNRNPH1, resulting in exon 2 skipping [43]. Thus, Hnrnph1 306 
regulation of Ipcef1 expression could represent an additional mechanism of Oprm1 regulation 307 
[44].  308 
The QTL that contains Hnrnph1 is predicted to perturb the neural development of the 309 
mesocorticolimbic circuitry that mediates MA behavior. Hnrnph1 (heterogeneous nuclear 310 
ribonucleoprotein) codes for an RNA binding protein (RBP) that is highly expressed throughout 311 
the brain, including the striatum, cortex, and hippocampus (Fig. S11) [34] and binds to G-rich 312 
elements to either enhance or silence splicing [45, 46].  hnRNPs such as Hnrnph1 form hnRNP-313 
RNA complexes to coordinate splicing of thousands of genes [46]. In addition, HNRNPH1 314 
regulates 3’ UTR cleavage and polyadenylation [47] and several hnRNPs export mRNAs to 315 
neuronal processes to regulate spatiotemporal translation and post-translational modifications 316 
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[48]. Synaptic activity can increase protein abundance of hnRNPs at the post-synaptic density of 317 
primary neurons [49]. The hippocampus contains focal expression of over 15 hnRNPs, including 318 
H1 (Fig. S11 [34]). Importantly, Hnrnph1 contains a glycine rich domain that permits 319 
nucleocytoplasmic shuttling via transportin 1 [50] and exhibits activity-dependent translocation 320 
to the cytoplasm [51]. Several hnRNPs exhibit activity-dependent localization at the synapse 321 
[49], suggesting additional neuronal functions of Hnrnph1 in addition to splicing. 322 
We identified Hnrnph1 as a quantitative trait gene responsible for MA sensitivity. 323 
However, the quantitative trait nucleotide(s) remain obscure. Hnrnph1 contains 18 genetic 324 
variants within the gene, including 15 intronic SNPs, a SNP in the 5’ UTR, a synonymous coding 325 
SNP, and a single T insertion in the 3’ UTR (Table S4 [52, 53]) that could cause brain region-326 
specific differential expression of Hnrnph1 and/or its ability to regulate splicing of its 327 
transcriptome-wide targets [46, 47]. We did not observe differential striatal expression of 328 
Hnrnph1 at the gene level or the exon level as a consequence of inheriting the Line 4a QTL 329 
(Figs. S5, S6). Our focus was limited to the striatum which is a behaviorally relevant region [16, 330 
29] that exhibits high Hnrnph1 expression during early adulthood (Fig. S11). Therefore, the QTL 331 
could influence Hnrnph1 expression at a different time period, in a different, behaviorally 332 
relevant brain region, or in a specific subpopulation of cells. Interestingly, striatal microarray 333 
datasets in BXD strains indicate an increase in Hnrnph1 expression from postnatal day 3 to 334 
postnatal day 14 as well as a change in the strain rank order of expression [30] which suggests 335 
that genotypic differences in Hnrnph1 expression could depend on the developmental time 336 
point. Finally, because excised introns can trans-regulate gene expression, an alternative 337 
explanation is that excised, SNP-containing introns from Hnrnph1 can function as polymorphic 338 
long noncoding RNAs to perturb their trans-regulation of the transcriptome [54].  339 
To our knowledge, there are no GWAS studies reporting genome-wide significant 340 
associations of HNRNPH1 variants with complex diseases or traits (http://www.ebi.ac.uk/gwas/). 341 
Interestingly, HNRNPH1 binding affinity and splicing can be modulated by genome-wide 342 
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significant SNPs associated with bipolar disorder, major depressive disorder, and 343 
schizophrenia, including rs1006737 (CACNA1C), rs2251219 (PBRM1), and rs1076560 (DRD2) 344 
[55]. Thus, HNRNPH1 splicing could profoundly impact the neurobiological mechanisms 345 
underlying these disorders. Additionally, HNRNPH1 and RBFOX1/2 coordinate splicing [56, 57] 346 
and knockdown RBFOX1 (an autism-associated RBP involved in neural development [58]) in 347 
human neural progenitor cells revealed over 200 alternatively spliced genes containing 348 
HNRNPH1 binding sites [56] and 524 genes containing binding sites for ELAVL2, a 349 
neurodevelopmental RBP [59] that was downregulated in Line 4a (Fig. 4).  350 
In summary, we identified Hnrnph1 as a quantitative trait gene for MA sensitivity. This is 351 
rarely accomplished in rodent forward genetic studies of behavior and will likely advance our 352 
understanding of the neurobiological basis of multiple neuropsychiatric disorders involving 353 
monoaminergic dysregulation. Identifying brain region- and cell type-specific splicing targets of 354 
Hnrnph1 could reveal therapeutic targets for these disorders, many of which have been 355 
associated with specific gene splicing events [55]. Furthermore, pharmacological perturbation of 356 
RBP function could one day serve as an effective therapeutic strategy. Recent findings in 357 
models of neurodegenerative disease show that targeting RBP signaling could be a promising 358 
treatment approach [60].  359 
 360 
Materials and Methods 361 
Mice 362 
All procedures in mice were approved by the Boston University and the University of 363 
Chicago Institutional Animal Care and Use Committees and were conducted in strict 364 
accordance with National Institute of Health guidelines for the care and use of laboratory 365 
animals.  Colony rooms were maintained on a 12:12 h light–dark cycle (lights on at 0600 h).  366 
Mice were housed in same-sex groups of two to five mice per cage with standard laboratory 367 
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chow and water available ad libitum. Age-matched mice were 50-100 days old at the time of 368 
testing (0900-1600 h).   369 
Locomotor activity 370 
For Lines 1-6 and Lines 4a-4h, locomotor activity was assessed in the open field [19].  371 
Briefly, congenics, subcongenics, and wild-type littermates were transported from the vivarium 372 
to the adjacent behavioral testing room where they habituated for at least 30 min prior to testing.  373 
Mice were then placed into clean holding cages with fresh bedding for approximately five min 374 
before receiving an injection of saline on Days 1 and 2 (10 µl/g, i.p) and an injection of 375 
methamphetamine on Day 3 (MA; 2 mg/kg, i.p.; Sigma-Aldrich®, St. Louis, MO USA).  Mice 376 
were placed into the center of the open field (37.5 cm x 37.5 cm x 35.7 cm; AccuScan 377 
Instruments, Columbus, OH USA) surrounded by a sound attenuating chamber 378 
(MedAssociates, St. Albans, VT USA) and the total distance traveled was recorded in six, 5 min 379 
bins over 30 min using VersaMax software (AccuScan).  380 
 Mice heterozygous for a frameshift deletion in Hnrnph1 (Hnrnph1 +/-) or Rufy1 (Rufy1 +/-) 381 
were engineered (http://www.bumc.bu.edu/transgenic/), bred, and phenotyped at Boston 382 
University School of Medicine. Mice were bred and phenotyped in a manner similar to the 383 
congenics at the University of Chicago, with the exception that the open field was a smaller size 384 
(43.2 cm long x 21.6 cm wide x 43.2 cm tall; Lafayette Instruments, Lafayette, IN USA) and 385 
mice were recorded daily for 1 h rather than 30 min to allow a more robust detection of the 386 
phenotype. Reduced MA sensitivity was also replicated in Hnrnph1 +/- mice using the 30 min 387 
protocol (Supplementary Information). Behavior was videotaped using a security camera system 388 
(Swann Communications, Pty., Ltd., Melbourne, Australia) and data were collected and 389 
analyzed using video tracking (Anymaze, Stoelting, Inc., Wood Dale, IL USA).  390 
Behavioral analysis 391 
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Because our primary focus was on MA-induced locomotor activity on Day 3, we first ran 392 
a two-way repeated measures ANOVA for Day 3 using genotype and sex as factors and time as 393 
the repeated measure. Because sex did not interact with genotype or time for any of the lines on 394 
Day 3, we combined sexes for the analysis of Days 1-3 and used repeated measures ANOVA 395 
with genotype as the main factor.  Main effects of genotype and genotype x time interactions 396 
were deconstructed using one-way ANOVAs and Fisher’s post-hoc test of each time bin or t-397 
tests in cases where there were two genotypes. A p-value of less than 0.05 was considered 398 
significant.  399 
QTL analysis of F2 mice 400 
B6 x D2-F2 mice (N = 676) were generated, maintained, genotyped, and analyzed as 401 
previously described [20, 22].  Genome-wide QTL analysis was performed in F2 mice using the 402 
R package QTLRel that contains a mixed model to account for relatedness among individuals 403 
[61]. We recently validated the use of permutation when estimating significance thresholds for 404 
mixed models [62]. Sex was included as an interactive covariate. For each analysis, significance 405 
thresholds (p < 0.05) were estimated using 1000 permutations. The F2 data and R code for are 406 
publicly available on github (https:/github.com/wevanjohnson/hnrnph1). 407 
Generation of congenics and subcongenics 408 
Lines 1 and 6 were obtained from Dr. Aldons Lusis’s laboratory at UCLA (Lines “11P” 409 
and “11M” [28]) and had previously been backcrossed to B6 for more than 10 generations.  410 
These lines contained homozygous, introgressed regions from D2 on an isogenic B6 411 
background that spanned chromosome 11.  Because Lines 1 and 6 contained such large 412 
congenic intervals, we first phenotyped non-littermate offspring derived from homozygous 413 
congenic breeders versus homozygous B6 wild-type breeders (The Jackson Laboratory, Bar 414 
Harbor, ME; Fig. 2; Fig. S2) rather than heterozygous-heterozygous breeders to avoid the 415 
otherwise high likelihood of introducing unmonitored recombination events. Thus, we ensured 416 
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that each individual possessed an identical genotype within each congenic line. The same type 417 
of control group is typically employed in the initial screen of chromosome substitution strains 418 
[19, 63, 64] which are essentially very large congenic lines.  We crossed Line 1 to B6 and 419 
phenotyped the F1 offspring alongside age-matched B6 mice. B6 cohorts were combined into a 420 
single group for the combined analysis of all three genotypes for Line 1 (homozygous for B6, 421 
homozygous for D2, and heterozygous; Fig. 2).   422 
 Next, we backcrossed Line 1 heterozygotes to B6 to generate subcongenic Lines 2-5 423 
(Fig. 2; Fig. S2).  Recombination events were monitored using genomic DNA extracted from tail 424 
biopsies and a series of TaqMan® SNP markers (Life TechnologiesTM; Carlsbad, CA; Table S1).  425 
We then used heterozygous-heterozygous breeding in Lines 2-5 to produce littermates of all 426 
three genotypes for simultaneous phenotyping (Fig. 2; Fig. S2). Because the QTL in Line 4 427 
represented the smallest congenic region and was dominantly inherited, we backcrossed Line 4 428 
heterozygotes to B6 to generate heterozygotes and wild-type littermates for Lines 4a-4h (Fig. 3; 429 
Fig. S3).  We used additional TaqMan® SNP markers (Life TechnologiesTM) to monitor 430 
recombination events and defined the precise congenic boundaries using PCR and Sanger 431 
sequencing of SNPs chosen from the Mouse Sanger SNP query database 432 
(http://www.sanger.ac.uk/cgi-bin/modelorgs/mousegenomes/snps.pl [52]). Genomic coordinates 433 
are based on mm9 (Build 37).   434 
 435 
Test for residual heterozygosity in Lines 4a, 4b, 4c, and 4d 436 
We assayed tail SNP DNA from one heterozygous congenic mouse and one B6 wildtype 437 
littermate from Lines 4a-4d (eight mice total) using services provided by the DartMouseTM Speed 438 
Congenic Core Facility at the Geisel School of Medicine at Dartmouth College 439 
(http://dartmouse.org/). A total of 882 informative B6/D2 SNPs were analyzed on the the 440 
GoldenGate Genotyping Assay (Illumina, Inc., San Diego, CA) using DartMouse’s SNaP-MapTM 441 
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and Map-SynthTM software to determine the allele at each SNP location. After detecting a single 442 
off-target locus on chromosome 3 (rs13477019; 23.7 Mb), we used a custom designed 443 
TaqMan® SNP marker for rs13477019 (Life Technologies, Carlsbad, CA USA) to confirm the 444 
result and to genotype additional samples from Lines 4a-4h for which we had both DNA and 445 
behavioral phenotypes. Data from this SNP marker were then used to test for the effect of 446 
genotype at the chromosome 3 locus on MA-induced locomotor activity.   447 
RNA-seq  448 
We harvested and pooled bilateral 2.5 mm diameter punches of the striatum for each individual 449 
sample from naïve, congenic mice and B6 wildtype littermates from Line 4a (N = 3 females and 450 
5 males per genotype; 50-70 days old). Total RNA was extracted as previously described [23] 451 
and purified using the RNeasy kit (Qiagen, Valencia, CA, USA). RNA was shipped to the 452 
University of Chicago Genomics Core Facility where cDNA libraries were prepared for 50 bp 453 
single-end reads according to the manufacturer’s instructions using the Illumina TruSeq® 454 
Stranded mRNA LT Kit (Part# RS-122-2101). Purified DNA was captured on an Illumina flow 455 
cell for cluster generation and sample libraries were sequenced at eight samples per lane over 456 
two lanes (technical replicates) on the Illumina HiSeq 2500 machine according to the 457 
manufacturer’s protocols. FASTQ files were quality checked via FASTQC and possessed Phred 458 
quality scores > 30 (i.e. less than 0.1% sequencing error). Using the FastX-Trimmer from the 459 
FastX-Toolkit, the 51st base was trimmed to enhance read quality and prevent misalignment. 460 
FASTQ files were utilized in TopHat [65]  to align reads to the reference genome (UCSC 461 
Genome Browser). Read counts per gene were quantified using the HTSeq Python package 462 
and the R Bioconductor package edgeR was used to analyze differential gene expression. 463 
EdgeR models read counts using a negative binomial distribution to account for variability in the 464 
number of reads via generalized linear models [66] . “Home cage” was included as a covariate 465 
in the statistical model to account for cage effects on gene expression. The p-values obtained 466 
for differential expression were then adjusted by applying a false discovery rate (FDR) method 467 
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to correct for multiple hypothesis testing [67]. The transcriptome dataset and code for RNA-seq 468 
analysis are available via NCBI Gene Expression Omnibus 469 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=cxkdoeaudvyhlqt&acc=GSE66366). 470 
Real-time quantitative PCR (qPCR) 471 
Oligo-dT primers were used to synthesize cDNA from total RNA to examine mRNA 472 
expression. Primer efficiencies for real-time quantitative PCR (qPCR) experiments were 473 
calculated using cycle threshold (CT) values (SYBR® Green; Life TechnologiesTM) derived from 474 
five, 10-fold serial cDNA dilutions; efficiencies (E) ranged from 90-100% (R2 = 0.99-1). Each 475 
sample was run in triplicate and averaged. Differential gene expression was reported as the 476 
fold-change in congenic or frameshift-deleted mice relative to B6 wild-type littermates using the 477 
2-(∆∆CT) method [68].  478 
Ingenuity Pathway Analysis (IPA) 479 
We used our differentially expressed gene list from the striatal transcriptome that 480 
contained both the log2 fold-change and p-values (FDR < 5%) and  applied IPA 481 
(www.qiagen.com/ingenuity) to identify enriched molecular pathways, functional annotations, 482 
gene networks, upstream causes, and predicted neurobiological consequences caused by 483 
inheritance of the QTL. IPA utilizes an algorithm that assumes that an increase in the number of 484 
molecular interactions indicates an increase in the likelihood of an effect on biological function. 485 
IPA uses a manually curated database (IPA Knowledge Base) containing the published 486 
literature to extract gene networks containing equally treated edges that directly and indirectly 487 
connect biologically related genes (www.qiagen.com/ingenuity). IPA analyses were conducted 488 
in February 2015.  489 
IPA Settings. We considered both direct and indirect relationships that were experimentally 490 
observed or moderately-to-highly predicted in all mammalian species, including mouse and rat. 491 
We used the “stringent” setting to filter molecules and relationships in tissues and cell lines. 492 
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With regard to mutations, we considered all functional effects, modes of inheritance, 493 
translational impacts, zygosity, wild-type, and unclassified mutation information. 494 
Canonical pathways. The ratio of the canonical pathways represents the number of genes in 495 
our gene list that overlap with the genes listed in the IPA-generated pathway divided by the total 496 
genes within the IPA-generated pathway; thus, a ratio equal to 1 represents perfect overlap. 497 
The –log10(p-value) for each canonical pathway was derived from the right-tailed Fisher’s exact 498 
that measured the degree of overlap between the number of genes identified in our list with the 499 
number of genes that comprise the canonical pathway versus the number of genes genome-500 
wide that would be expected to overlap by chance. The p-values were corrected for multiple 501 
testing using the Benjamini-Hochberg method [67] and represent the FDR. 502 
Diseases, functions, and gene networks. The statistical significance of overlap between 503 
our gene list and a particular disease or function was assessed using the p-value derived from a 504 
Fisher’s exact test. The predicted activation state was assessed by calculating a z-score that 505 
determined the statistical significance of the match between the observed and predicted 506 
direction. “Increased” or “decreased” indicates that the Z-score was significant for predicting 507 
activated or inhibited state. IPA networks were built based on the degree of connectivity 508 
between genes within our gene list, starting with the most connected genes. Genes were added 509 
by the IPA algorithm to the network to facilitate connectivity. Networks were limited to a 510 
maximum of 35 genes to facilitate interpretability and the ability to generate hypotheses. The 511 
Network Score (see Table S10), a.k.a., the “p score”, represents the –log10 (p-value) and 512 
represents the probability of finding the observed number of focus genes in a network by 513 
chance.  514 
Upstream regulator analysis. This analysis identifies causal molecules associated with 515 
differential expression using both the significance and the direction of differential expression to 516 
specify causal predictions. Several plausible causal networks are constructed and used to 517 
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calculate an enrichment score and p-value based on overlap between predicted and observed 518 
regulator-regulated genes (Fishers exact test). A Z-score is also calculated that determines the 519 
degree of match between observed and predicted direction of gene expression (+ or - [69]). 520 
“Increased” or “decreased” indicates that the Z-score was significant for predicting activation or 521 
inhibition of the regulator. 522 
GeneNetwork 523 
To identify published cis- and trans- eQTLs that could explain gene expression 524 
differences caused by inheritance of the Line 4a congenic interval, we queried differentially 525 
expressed genes (FDR < 20%; 174 genes total; Table S6) in transcriptome datasets from 526 
several brain regions in GeneNetwork [30] involving BXD recombinant inbred strains 527 
(recombinant inbred strains derived from B6 and D2 strains). We considered cis- and trans-528 
QTLs originating from SNPs located within the 50-60 Mb locus and employed an arbitrary cut-off 529 
of LRS ≥ 13.8 (LOD ≥ 3). We only included genes where there was an exact match of gene with 530 
the LRS location using the appropriate genome build coordinates for each dataset.  531 
Generation of TALENs-targeted Hnrnph1 +/- and Rufy1 +/- mice 532 
TALENs vectors encoded either the right or left arm of the TALE effector that targeted 533 
the first coding exons of Hnrnph1 or Rufy1 (Cellectis Bioresearch Inc., Paris, France). Upon 534 
bacterial cloning and purification, TALENs vectors containing a T7 promoter were linearized and 535 
used as templates for in vitro mRNA synthesis (mMessage mMachine T7 transcription kit; Life 536 
Technologies), and purified using MEGAclear transcription clean-up kit (Life Technologies). 537 
Each mRNA cocktail was diluted in sterile buffer and injected into B6 single-cell embryos at the 538 
BUMC Transgenic Core facility (http://www.bumc.bu.edu/transgenic/). We developed a 539 
genotyping assay utilizing native restriction enzyme recognition sites within the TALENs FokI 540 
cleavage domain. Genomic DNA was extracted from mouse tail biopsies and PCR-amplified 541 
with primers targeting100 base pairs upstream and downstream of the TALENs binding domain. 542 
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Amplicons were then exposed to restriction digest overnight, run on a 2% agarose Ethidium 543 
Bromide Tris-Borate-EDTA gel, and imaged with ultraviolet light. TALENs-targeted deletions 544 
were identified by the presence of undigested bands caused by a loss of the restriction site. To 545 
confirm base pair deletions in our founder lines, undigested restriction enzyme-exposed PCR 546 
amplicon bands were excised, gel-purified, and vector-ligated overnight at 4ºC using the pGEM 547 
T-easy Vector Systems (Promega). The ligation reaction was transformed into MAX Efficiency 548 
DH5α Competent Cells (Invitrogen) and plated onto Ampicillin-IPTG/X-Gal LB agarose plates for 549 
blue-white selection. Following overnight incubation at 37°C, white colonies were picked, 550 
cultured in ampicillin-enriched LB medium, and amplified. The PCR product was purified using 551 
the QIAprep Miniprep kit (QIAGEN). We then sequenced the vectors for the deletions using the 552 
pGEM T7 site upstream of the insert.  553 
Genotyping of TALENs-targeted Hnrnph1 +/- and Rufy1 +/- mice 554 
An Hnrnph1 forward primer (GTTTTCTCAGACGCGTTCCT) and reverse primer 555 
(ACTGACAACTCCCGCCTCA) were designed to target upstream and downstream of the 556 
TALENs binding domain in exon 4 of Hnrnph1. Genomic DNA was used to amplify a 204 bp 557 
PCR product using DreamTaq Green PCR Mastermix (ThermoScientific). PCR products were 558 
treated with the BstNI restriction enzyme (New England Biolabs) or a control enzyme-free buffer 559 
solution and incubated overnight at 60°C to ensure complete digestion. Enzyme-treated PCR 560 
products and untreated controls were resolved in 2% agarose gel electrophoresis with 0.5 561 
μg/mL ethidium bromide to visualize under UV light. There were two BstNI restriction sites within 562 
the Hnrnph1 amplicon that were located proximal and distal to the TALENs FokI cleavage zone. 563 
Mice heterozygous for the Hnrnph1 deletion showed two bands on the gel, while B6 controls 564 
showed a single band.  565 
 Similar to Hnrnph1, a Rufy1 forward primer (AATCGTACTTTCCCGAATGC) and reverse 566 
primer (GGACTCTAGGCCTGCTTGG) targeted upstream and downstream of the TALENs 567 
binding domain in the first coding exon (exon 1). The 230 bp PCR amplicon contained a SacII 568 
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restriction site that was deleted in Rufy1 +/- mice. Thus, Rufy1 +/+ mice showed a single, smaller 569 
digested band whereas Rufy1 +/- mice showed both the digested band as well as a larger, 570 
undigested band. 571 
Assessment of potential off-target deletion of Hnrnph2 in Hnrnph1-targeted mice.  572 
To assess off-target activity in Hnrnph1-targeted mice, we used the UCSC genome 573 
browser to BLAT the TALENs binding domains and identified a single homologous region 574 
located within the first coding exon of Hnrnph2. We used the same PCR- and gel-based assay 575 
to test for the deletion in Hnrnph2 with the exception that we used forward 576 
(GCCACCAAGAGTCCATCAGT) and reverse primers (AATGCTTCACCACTCGGTCT) that 577 
uniquely amplified a homologous 197 bp sequence within Hnrnph2 that contained a single 578 
Bstn1 restriction site. Digestion at the Bstn1 site produced an 81 bp band and a 115 bp band. 579 
 580 
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 587 
Figure Legends 588 
Figure 1.  QTL for reduced MA sensitivity (D2 < B6) in B6 x D2-F2 mice.  (a): We previously 589 
published a genome-wide a significant QTL on chromosome 11 for MA-induced locomotor 590 
activity from the same B6 x D2-F2 dataset (N = 676) that was significant when the data were 591 
summed from 15-30 min and 0-30 min but not when the data were summed from 0-15 min [20]. 592 
To further dissect the time dependency of this locus, we generated LOD scores from the same 593 
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mice in six, 5-min time bins over 30 min. The x-axis represents the physical distance (Mb) of the 594 
marker on chromosome 11 (mm9). The y-axis represents the LOD score. The dashed, 595 
horizontal line represents the genome-wide significance level derived from 1,000 permutations. 596 
The dark blue QTL trace (5 min) denotes a distal locus (90 Mb) in which inheritance of the D2 597 
allele caused an increase in locomotor activity relative to the B6 allele that was most likely not 598 
associated with MA treatment (see QTL for Days 1 and 2 in response to saline; Fig. S1; D2 > 599 
B6). The remaining red- and pink-shaded QTL traces denote a separate locus (50 Mb) that was 600 
specific for MA treatment on Day 3 in which inheritance of the D2 allele caused a decrease in 601 
MA-induced locomotor activity. The dashed QTL trace indicates the time bin containing the peak 602 
LOD score. (b): The effect plot for the marker nearest the peak LOD score is shown for the six, 603 
5-min time bins. Data are sorted by genotype for each time bin. The time bin with the most 604 
significant LOD score is circled. B6 = homozygous for B6 allele (circles); H = heterozygous 605 
(triangles); D2 = homozygous for D2 allele (colored squares). Data are presented as the mean ± 606 
S.E.M. 607 
Figure 2. Congenic analysis identifies Line 4 for fine mapping. Statistical results are 608 
provided in Table S3 and described in the Supplementary Information. (a): Lines 1-6 possessed 609 
either one (heterozygous; “H”) or two copies (homozygous, “D2”) of a chromosome 11 interval 610 
from the D2 inbred strain (gray region) on an isogenic B6 background (black region; denotes the 611 
genotype for the rest of the genome). The white regions represent transitional regions that were 612 
not genotyped. The x-axis represents the physical position (Mb) of the SNP marker. The SNP 613 
markers that were used to genotype Lines 1-6 are listed in Table S1. The y-axis represents the 614 
LOD score for the F2-derived QTL that was causally associated with reduced MA sensitivity on 615 
Day 3 (D2 < B6; Figure 1; 25 min bin). (+) = congenic line captured the QTL for reduced MA 616 
sensitivity on Day 3.  (-) = congenic line failed to capture the QTL. (b-e): The three columns 617 
represent the phenotypes for Days 1, 2, and 3. The four rows represent Lines 1-4. The negative 618 
results for Lines 5 and 6 (-) are shown in Figure S2. “*” indicates a dominant effect of the D2 619 
25 
 
allele (D2 = H < B6) or H < B6. “$” indicates an additive effect (D2 < H < B6).  “#” indicates a 620 
recessive effect (D2 < H = B6). “%” indicates that B6 and D2 differ from each other but not from 621 
H.  “&” indicates that H and D2 differ from each other but not from B6. Data are represented as 622 
the mean ± S.E.M. p < 0.05 was considered significant. We estimated the narrow-sense 623 
heritability of the QTLs (h2) for Line 3 and Line 4 (25 min) based on the intraclass correlation 624 
coefficient using the phenotypic variances from homozygous D2 versus homozygous B6 mice 625 
according to the following formula: h2 = (between-genotype variance) / (between-genotype 626 
variance + within-genotype variance). For Line 3, h2 = 0.35; for Line 4, h2 = 0.08. Although these 627 
h2 estimates do not contain confidence intervals, the differences in h2 values combined with the 628 
different modes of inheritance suggest that Line 3 and Line 4 possess different QTLs.    629 
Figure 3.  Analysis of subcongenic lines from Line 4 reveals a 206 kb critical interval for 630 
reduced MA sensitivity. Statistical results are provided in Table S3 and described in the 631 
Supplementary Information. (a): Lines 4a-4h possessed heterozygous (H) intervals of B6 and 632 
D2 origin (gray regions) on an isogenic B6 background (black; denotes the genotype for the rest 633 
of the genome). The white regions represent transitional regions that were not genotyped. The 634 
x-axis represents the physical position (Mb) on chromosome 11. The SNP markers used for 635 
genotyping Lines 4a-4h are listed in Table S2. The y-axis represents the peak LOD score for the 636 
F2-derived QTL causing reduced MA sensitivity on Day 3 (Figure 1c; 25 min; white QTL trace). 637 
(+) = subcongenic line captured the QTL for reduced MA sensitivity.  (-) = subcongenic line 638 
failed to capture the QTL. (b-d): The three columns represent the phenotypes for Days 1, 2, and 639 
3. The three rows represent Lines 4a-4c. The negative results for Lines 4d-4h (-) are shown in 640 
Figure S3. “*” = significantly different from B6 (p < 0.05). Data are represented as the mean ± 641 
S.E.M. (e): The proximal boundary of Line 4b (+) and the proximal boundary of Line 4c (-) 642 
define the 206 Kb critical interval (crit. int.; 50,185,512-50,391,845 bp; mm9; Table S2) which 643 
contains two protein coding genes - Hnrnph1 and Rufy1.  644 
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Figure 4. Transcriptome analysis of Line 4a identifies “Cellular Development, Nervous 645 
System Development and Function, Behavior” as the top IPA network. (a, b): 17 646 
downregulated genes (green) and four upregulated genes (red) were identified in the IPA 647 
network (Table S10). Genes in the network diagram that lack any color were included by the 648 
IPA algorithm to facilitate connectivity. Chromosome and position (Chr/Pos; mm9) of each gene 649 
is shown. P = p-value of differential expression in Line 4a; FC = fold-change in expression; FDR 650 
= false discovery rate (< 0.05; 5%), P Rank = rank in p-value (#1 = lowest p-value out of 91 651 
genes); FC Rank = rank in fold-change (#1 = largest fold-change out of 91 genes). 652 
Figure 5. TALENS-targeted frameshift deletions in Hnrnph1 +/- mice reveal Hnrnph1 as a 653 
quantitative trait gene for MA sensitivity.  (a): Left TAL effector (50,191,867-50,191,883 bp) 654 
and right TAL effector (50,191,899-50,191,915 bp) separated by the FokI cleavage zone were 655 
used to introduce frameshift deletions in the first coding exon of Hnrnph1 (exon 4) that resulted 656 
in premature stop codons (Fig. S8). Founder #28 contained a 16 bp deletion and Founder #22 657 
contained an 11 bp deletion. (b): A PCR amplicon capturing the FokI cleavage zone was 658 
digested with BstNI. Hnrnph1 +/+ mice contained two copies of a functional BstNI restriction site 659 
and thus, restriction digest produced a single band containing digested fragments of equal size. 660 
Hnrnph1 +/- mice were heterozygous for a deletion of the BstNI site and showed both the 661 
digested band and a larger, undigested band. Gel band lanes were cropped and re-ordered to 662 
present wild-type first (+/+) followed by B6 control, and heterozygous samples (+/-). (c): There 663 
was a significant upregulation of total Hnrnph1 transcript levels in Hnrnph1 +/- mice as indicated 664 
by cDNA amplification using qPCR primers spanning exons 4-5 that hybridized to both 665 
genotypes (t6 = 5.69; p = 0.0013). (d): An upregulation of total Hnrnph1 transcript levels was 666 
also indicated by cDNA amplification using qPCR primers spanning untargeted exons 6-7 (t6 = 667 
8.53; p = 0.00014). (e): A significant downregulation of the  Hnrnph1 +/+ transcript levels was 668 
observed in Hnrnph1 +/- mice that was indicated by cDNA amplification using primers spanning 669 
exons 4-5, one of which hybridized to the deleted Hnrnph1 +/+ sequence (t6 = 9.45; p = 0.00091; 670 
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Fig. 5e). *p < 0.05.  (f): In Line #28, there was no effect of genotype on locomotor activity in 671 
response to saline (SAL) on Days 1 or 2 (left, middle panels). On Day 3, Hnrnph1 +/- mice from 672 
Line #28 heterozygotes showed a significant reduction in MA-induced locomotor activity 673 
compared to Hnrnph1 +/+ littermates (right panel). (g): In Line #22, there was no effect of 674 
genotype on locomotor activity in response to SAL on Days 1 or 2 (left, middle panels). On Day 675 
3, Hnrnph1 +/- mice from Line #22 showed significantly reduced MA-induced locomotor activity 676 
compared to Hnrnph1 +/+ littermates. Data are presented as the mean ± S.E.M. * = significant 677 
genotype x time interaction followed by unpaired t-tests of individual time bins (p < 0.05; Table 678 
S3; Supplementary Information).  679 
Figure 6. TALENS-targeted frameshift deletion in Rufy1 +/- mice.  (a): A left TALE effector 680 
(50,244,600-50,244,616 bp) and a right TALE effector (50,244,569-50,244,585 bp) separated by 681 
the FokI cleavage zone were used to introduce a frameshift deletion that resulted in a premature 682 
stop codon in the first coding exon of Rufy1 (see Fig. S8). (b): A PCR amplicon was generated 683 
that captured the FokI cleavage zone and a single SacII restriction site and was subjected to 684 
restriction digest with SacII. Rufy1 +/+ mice contained the SacII restriction site and thus, showed 685 
only a single, smaller band. Rufy1 +/- mice showed both the SacII-digested band and a larger, 686 
undigested band, indicating the presence of the deletion. (c): There was no effect of genotype 687 
or genotype x time interaction in Rufy1 +/- versus Rufy1 +/+ mice from Line #3 on Days 1, 2, or 3 688 
(p > 0.05; Table S3). Data are presented as the mean ± S.E.M.  689 
690 
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Supplementary Table 1: SNPs that define Lines 1 through 6. B6 = homozygous for 691 
C57BL/6J; D2 = homozygous for DBA/2J; H = heterozygous; ARRAY = SNP array-based 692 
genotyping; TAQMAN = custom-designed fluorescent SNP genotping; SEQ = Sanger 693 
sequencing-based genotyping; ND = not determined 694 
 695 
Supplementary Table 2: SNPs that define Lines 4a-4h. SNP ID, chromosome 11 location 696 
(mm9) method of genotyping, and genotypes are listed. B6 = homozygous for C57BL/6J; D2 = 697 
homozygous for DBA/2J; H = heterozygous; ARRAY = SNP array-based genotyping;  698 
SEQ/TAQ = SNPs were both Sanger-sequenced and genotyped using custom-designed 699 
Taqman fluorescent SNP genotyping; SEQ = Sanger sequencing-based genotyping; NI = non-700 
informative; ND = not determined. Red-filled cells denote the critical interval spanning 701 
50,185,512-50,391,845 bp. 702 
 703 
Supplementary Table 3: ANOVA tables for congenic lines and TALENs-targeted lines. F 704 
statistics and p-values are listed for Days 1, 2, and 3 for the effect of genotype (Geno) and 705 
Geno x Time interactions as well as significant time bins.  706 
 707 
Supplementary Table 4: Genetic variants between B6 and D2 within critical interval. Data 708 
(mm9) were obtained from the Sanger mouse query tool containing genetic variants 709 
(http://www.sanger.ac.uk/resources/mouse/genomes/).  710 
 711 
Supplementary Table 5: Residual heterozygosity in Lines 4a through 4d. One mouse for 712 
each genotype (B6 = homozygous for B6 allele; H = heterozygous for B6 and D2 alleles) from 713 
each of the four congenic lines (Lines 4a, 4b, 4c, and 4d) were genotyped using services 714 
provided by DartMouse. The SNP ID, chromosome (Chr.), physical position (Build 34), and 715 
genotype are listed. Each SNP allele is represented by either “A” or “B” and the reference allele 716 
(“JAX B6”) which could be either AA or BB. NC = no call. 717 
Supplementary Table 6: Differentially expressed genes in the striatum of Line 4a. Gene 718 
ID, gene name, physical position and build, log2 fold-change, fold-change (FC), P-value, and Q-719 
value are listed in order of ascending p-value.   720 
 721 
Supplementary Table 7: Primer sequences used for qPCR. Genes, targeted exons, forward 722 
and reverse sequences, and amplicon size (bp) are listed. 723 
Supplementary Table 8: Canonical pathways in IPA. The pathway, -logP, ratio, z-score, and 724 
genes (“Molecules”) identified from our list are shown.  The top 20 annotations are listed. 725 
Supplementary Table 9: Diseases and functions annotations. The z-score indicates the 726 
degree of match between the observed and predicted “Increased” or “decreased” denotes those 727 
Z-score that were significant.disease or function. The top 20 annotations are shown.  728 
Supplementary Table 10: Top IPA networks containing disease and functions 729 
annotations. Score [p score; -log10(p-value], number of focus genes identified from our gene 730 
list, and names of diseases and function associated with each network are shown. 731 
Supplementary Figure 1: Distal QTL on chromosome 11 (90 Mb) for Days 1 and 2 that 732 
increased locomotor activity in response to saline (D2 > B6). We previously published a 733 
genome-wide significant QTL on chromosome 11 for Day 1 and Day 2 from this B6 x D2-F2 734 
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dataset that was significant from 0-15 min and from 15-30 min 20. Here, we report the LOD 735 
scores from the same dataset in six, 5-min time bins over 30 min. (a, b): QTL plots are shown 736 
for the time bins on Day 1 (saline; SAL, i.p.) and Day 2 (SAL, i.p.). The x-axis represents the 737 
physical location of the marker (Mb). The y-axis represents the LOD score. The dashed, 738 
horizontal line represents the genome-wide significance threshold derived from 1,000 739 
permutations. The dashed QTL trace indicates the time bin containing the most significant LOD 740 
score for each day. The peak LOD was observed at approximately 90 Mb; this same QTL was 741 
also present on Day 3 at the first 5-min bin prior to the behavioral onset of MA (Fig. 1a). (c, d): 742 
Effect plot of the marker with the most significant LOD scores is shown for Day 1 and Day 2 in 743 
5-min time bins. Data are sorted by genotype at the marker rs3710148 (96.4 Mb) for each time 744 
bin. The time bin with the most significant LOD score is circled. B6 = homozygous for the B6 745 
allele (black circles); H = heterozygous (open triangles); D2 = homozygous for the D2 allele 746 
(colored squares). Data are presented as the mean ± S.E.M. 747 
 748 
Supplementary Figure 2: MA sensitivity in Line 5 and Line 6. Lines 5 and 6 possessed 749 
chromosome 11 intervals from the D2 strain on an isogenic B6 background (see Figure 2a). The 750 
SNPs used to define the intervals in Lines 5 and 6 are listed in Table S1. (a, b): The three 751 
columns represent the locomotor phenotypes for Days 1, 2, and 3 for Line 5 and Line 6.  752 
Sample sizes (N) are listed for each genotype. Data are presented as the mean ± S.E.M.  753 
Statistical analyses are included in Table S3. 754 
 755 
Supplementary Figure 3: MA sensitivity in Lines 4d-4h. Lines 4d-4h were derived from Line 756 
4 and possessed heterozygous intervals from the D2 strain on an isogenic B6 background (see 757 
Fig. 3a). The SNPs used to define Lines 4d-h are listed in Table S2. (a-e): The three columns 758 
represent the locomotor phenotypes for Days 1, 2, and 3. The five rows (a-e) represent the 759 
phenotypes for Lines 4d-4h, respectively. Sample sizes (N) are listed for each genotype. There 760 
was no effect of genotype or genotype x time interaction on MA-induced locomotor activity for 761 
any of these lines (see Table S3). Data are presented as the mean ± S.E.M.  762 
 763 
Supplementary Figure 4: Physical map of the 882 genome-wide informative markers used 764 
to ascertain residual heterozygosity in Lines 4a-4d.  (a): The sample that is shown is a Line 765 
4a heterozygous mouse that was genotyped with the GoldenGate SNP microarray (services 766 
and figure were provided by DartMouseTM; http://dartmouse.org/). As expected, this mouse was 767 
heterozygous for B6 and D2 alleles at all three SNP markers within the Line 4a congenic region 768 
on chromosome 11 (purple, horizontal ticks). Additionally, this mouse was heterozygous at a 769 
marker located on chromosome 3 (rs13477019; 23.7 Mb; purple, horizontal tick). This region of 770 
residual heterozygosity also segregated in Lines 4b-4h. All other markers were genotyped as 771 
homozygous for the B6 allele (green, horizontal ticks). Table S5 lists the complete set of SNPs 772 
and genotypes for the eight samples tested on the array. (b): When sorting by genotype on 773 
chromosome 3 (rs13477019) in 115 mice from Lines 4a-4h for which we had both genotypic and 774 
phenotypic information available, there was no effect of genotype (F2,112 < 1) or genotype x time 775 
interaction with regard to MA sensitivity (F5,560 < 1). Data are presented as the mean ± S.E.M. 776 
 777 
Supplementary Figure 5: qPCR results for Hnrnph1 and Rufy1 expression in the striatum 778 
in Line 4a. (a): Heterozygous (H) mice (N = 8) showed significantly reduced Nurr1 expression 779 
relative to B6 (N= 8; t14 = 2.18; p = 0.047). (b, c):  There was no significant difference in 780 
expression of Hnrnph1 (exons 12-13; t29 < 1) or Rufy1 (exons 16-17; t29 = 1.51; p = 0.14) in B6 781 
(N = 14) versus H (N = 17) mice. Data are presented as the mean ± S.E.M. Primer sequences 782 
are listed in Table S7. 783 
Supplementary Figure 6: Exon-level read counts for Hnrnph1 and Rufy1 in Line 4a using 784 
Integrated Genome Browser. (a, b): The x-axis represents the physical location (bp) of the 785 
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annotated exons (vertical lines, UCSC Genome Browser; mm9) on chromosome 11 for Hnrnph1 786 
and Rufy1. The y-axis represents the summed read counts (y-axis) across all 8 samples for 787 
each genotype (B6, H). Note that different scales are used on the y-axis for Hnrnph1 (the more 788 
highly expressed gene; 0-2500 reads) versus Rufy1 (0-300 reads).  789 
 790 
Supplementary Figure 7: Htt and Creb1 are the top two IPA upstream regulators of the 791 
striatal transcriptome in Line 4a. Arrows pointing toward genes indicate predicted activation; 792 
horizontal, perpendicular lines indicate predicted inhibition. Green and red colors indicate 793 
downregulated or upregulated genes in our dataset. Purple circles denote genes that overlap 794 
between Htt (a) and Creb1 (b). The legend on the right hand side denotes the biological 795 
classification for each gene contained in the regulator diagrams. 796 
 797 
Supplementary Figure 8: TALENs-targeted Hnrnph1 and Rufy1 deletions produce 798 
frameshift mutations that result in premature stop codons. We used the ExPASy Translate 799 
Tool (http://web.expasy.org/translate/ to input wild-type and deleted cDNA sequences to obtain 800 
protein sequences. (a-c): Amino acid sequence is shown for Hnrnph1 +/+  mice and Hnrnph1 +/- 801 
founders. (d, e): Amino acid sequence is shown for Rufy1 +/+ and Rufy1 +/- founders. Methionine 802 
(Met) is shown in green. A red “Stop” denotes a stop codon.  803 
 804 
 Supplementary Figure 9: No off-target deletions in the highly homologous Hnrnph2 gene 805 
and no compensatory change in Hnrnph2 expression in Hnrnph1 +/- mice. (a): A 197 bp 806 
PCR amplicon was generated using primers specific for exon 4 of Hnrnph2 and contained the 807 
same homologous BstNI cut site as exon 4 in Hnrnph1 (Figure 5). Hnrnph1 +/+ mice and 808 
Hnrnph1 +/- founder mice (#28 and #22) that were heterozygous for an Hnrnph1 frameshift 809 
deletion all showed two bands following restriction digest, indicating that there was no deletion 810 
of the restriction site in Hnrnph2. (b): There was no compensatory change in Hnrnph2 811 
expression in Line #28 when comparing Hnrnph1+/- (N = 4) versus Hnrnph1 +/+ (N = 4) mice (t6 < 812 
1). Data are presented as the mean ± S.E.M.  813 
 814 
Supplementary Figure 10: Reduced MA sensitivity in TALENs-targeted Hnrnph1+/- mice 815 
(Founder #28 Line) following 30 min training sessions. (a): For Day 1, there was no effect of 816 
genotype (F1,32 < 1) nor any interaction with time (F5,160 <1). (b): For Day 2, there was no effect 817 
of genotype (F1,32 = 3.79; p = 0.06) but there was a significant genotype x time interaction (F5,160 818 
= 3.66; p = 0.0037 that was explained by Hnrnph 1+/- mice showing significantly greater 819 
locomotor activity than Hnrnph1 +/+ mice at the 5-min and 10-min time bins (t32 = 2.53, 2.42; p = 820 
0.017, 0.021). (c): For Day 3, there was an effect of genotype (F1,32 = 5.37; p = 0.027) but no 821 
significant genotype x time interaction (F5,160 = 2.04; p = 0.076). Hnrnph1+/- mice showed 822 
significantly less MA-induced locomotor activity than Hnrnph1 +/+ mice at 25 and 30 min (t32 = 823 
2.07, 3.03; p = 0.046, 0.0048). Data are presented as the mean ± S.E.M.  *p < 0.05. 824 
 825 
Supplementary Figure 11: Mid-sagittal, in situ hybridization sections for Hnrnph1 and 826 
Rufy1. In situ hybridization staining of mid-sagittal sections are shown for Hnrnph1 (panel a) 827 
and Rufy1 (panel b) and were obtained from the Allen Institute for Brain Science 828 
(http://www.brain-map.org/ 4). Hnrnph1 clearly shows higher expression than Rufy1 which can 829 
also evident in the number of read counts in our dataset (see also Fig. S6).  830 
 831 
832 
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Table 1. WebGestalt-Gene Onotology (GO) analysis of differentially expressed genes in 833 
the striatum of Line 4a. GO enrichment analysis of our gene list (91 genes, FDR < 5%) was 834 
performed using a hypergenometric statistical procedure and multiple testing adjustment (Adj 835 
P). A minimum of two genes was required per category. 836 
Biological Process GO ID P Adj P 
# of 
Genes 
Synaptic transmission 0007268 6.40E-12 2.07E-09 16 
Multicellular organismal signaling 0035637 3.36E-12 2.07E-09 18 
Transmission of nerve impulse 0019226 1.84E-11 3.97E-09 17 
Cell-cell signaling 0007267 1.09E-09 1.77E-07 17 
Single-organism process 0044699 1.91E-08 2.48E-06 54 
Multicellular organismal process 0032501 5.60E-07 4.54E-05 43 
Biological regulation 0065007 5.46E-07 4.54E-05 57 
Single-multicellular organism process 0044707 5.25E-07 4.54E-05 43 
Single organism signaling 0044700 1.25E-06 8.10E-05 39 
Signaling 0023052 1.25E-06 8.10E-05 39 
     
Molecular Function GO ID P Adj P 
# of 
Genes 
Transporter activity 0005215 1.74E-06 2.00E-04 16 
Transmembrane transporter activity 0022857 1.59E-05 1.10E-03 13 
Secondary active transmembrane 
transporter activity 0015291 4.94E-05 1.80E-03 6 
Alpha1-adrenergic receptor activity 0004937 4.10E-05 1.80E-03 2 
Substrate-specific transporter activity 0022892 1.00E-04 2.40E-03 12 
Substrate-specific transmembrane 
transporter activity 0022891 1.00E-04 2.40E-03 11 
Anion transmembrane transporter activity 0008509 2.00E-04 3.60E-03 6 
Transmembrane transporter activity 0015075 4.00E-04 6.30E-03 10 
Adrenergic receptor activity 0004935 5.00E-04 6.60E-03 2 
     
Cellular Component GO ID P Adj P 
# of 
Genes 
Cell junction 0030054 8.26E-08 9.17E-06 15 
Synapse 0045202 1.07E-06 5.94E-05 12 
Plasma membrane 0005886 3.63E-06 1.00E-04 31 
Cell periphery 0071944 6.17E-06 2.00E-04 31 
Synapse part 0044456 1.87E-05 4.00E-04 9 
Cell part 0005623 2.00E-04 3.20E-03 66 
Neuron spine 0044309 4.00E-04 4.90E-03 5 
Dendritic spine 0043197 4.00E-04 4.90E-03 5 
Postsynaptic membrane 0045211 6.00E-04 6.70E-03 5 
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Table 2. Differentially expressed genes in Line 4a (FDR < 20%) that possessed cis- or trans-eQTLs in GeneNetwork (GN). 
Differentially expressed genes (DEGs) are shown from our striatal RNA-seq dataset (FDR < 20%) that possess known eQTLs from 
GeneNetwork caused by genetic variation within the Line 4a locus (chromosome 11: 50-60 Mb). With regard to DEGs from our 
dataset: Chr/Pos = chromosome and position of each DEG; FC=fold-change; P = p-value; Q = q-value. With regard to eQTLs 
identified in GeneNetwork: The GeneNetwork genes associated with differential expression of DEGs from our dataset are listed 
[LRS ≥ 13.8 (LOD ≥ 3)]; NAc = nucleus accumbens; Str = striatum; NCTX = neocortex; PFC = prefrontal cortex; HC = hippocampus;  
LRS = likelihood ratio statistic; GN = GeneNetwork. eQTLs were identified from the following datasets: UTHSC Hippocampus 
Illumina v6.1 All Combined (Nov12) RankInv Database; Hippocampus Consortium M430v2 (Jun06) PDNN Database UTHSC 
Hippocampus Illumina v6.1 NON (Sep09) RankInv Database; Hippocampus Consortium M430v2 (Jun06) RMA Database; BIDMC-
UTHSC Dev Neocortex P3 ILMv6.2 (Nov11) RankInv Database; BIDMC-UTHSC Dev Neocortex P14 ILMv6.2 (Nov11) RankInv 
Database; HQF BXD Neocortex ILM6v1.1 (Dec10v2) RankInv Database; HQF BXD Neocortex ILM6v1.1 (Feb08) RankInv Database; 
VCU BXD NAc Sal M430 2.0 (Oct07) RMA Database; HQF Striatum Affy Mouse Exon 1.0ST Gene Level (Dec09) RMA Database; 
HQF BXD Striatum ILM6.1 (Dec10v2) RankInv Database; HBP Rosen Striatum M430V2 (Apr05) RMA Clean Database 
33 
 
 
Gene ID for 
DEG 
 (RNA-seq) 
Gene name 
(RNA-seq) 
Chr/Pos 
of DEG 
(Mb) 
Log2FC 
of DEG  
(± FC) 
P-value 
of DEG  
FDR of 
DEG  
Associated GeneNetwork 
genes within Line 4a region  
eQTL 
LRS  
Brain 
Region 
Slc8a1 
solute carrier family 8 
(sodium/calcium exchanger), 
member 1 17:81.77 
-0.59  
(-1.50) 2.9x10-7 3.3x10-4 Olfr51 (50.8 Mb) 19.1 NTCX 
Satb1 
special AT-rich sequence 
binding protein 1  17:51.87 
-0.35  
(-1.27) 3.1x10-5 9.4x10-3 B130040O20Rik (49.8 Mb) 18.2 NCTX 
Obscn 
 
 
 
 
obscurin 11:50.89 
1.23  
(+2.34) 1.9x10-5 0.01 
2610507I01Rik,Mrpl55,D1300
47N11Rik,Gja12,Guk1, 
2810021J22Rik (50-59 Mb) 20-82 
NAc, Str, 
NCTX, 
PFC, 
Hipp 
Megf11 
 multiple EGF-like-domains 11 9: 64.23 
-0.46    
(-1.38) 4.5x10-5 0.01 
Mprip (59.5 Mb),Tom1l2 (60.0 
Mb) 
14.3, 
14.4 
NAc, 
NCTX 
Malat1 
metastasis associated lung 
adenocarcinoma transcript 1 19:5.79 
-0.68 
(1.60) 1.2x10-4 0.023 
Il3 (54.0 Mb) 
 15.1 NCTX 
Mkx 
 
mohawk homeobox 18:6.93 
-0.47    
(-1.38) 5.1x10-4 0.07 Olfr323 (58.4 Mb) 16.0 NCTX 
Hs3st2 
heparan sulfate 3-O-
sulfotransferase 2 7:128.53 
-0.52    
(-1.43) 8.5x10-4 0.11 Cops3 (59.6 Mb) 14.4 PFC 
Ipcef1 
interaction protein for 
cytohesin exchange factors 1  10:3.37 
-0.57    
(-1.48) 1.1x10-3 0.12 
Hnrnph1 (50.2 Mb), G3bp1 
(55.3 Mb) 
15.1, 
18.8 NCTX 
Tgm2 
transglutaminase 2, C 
polypeptide 2:157.95 
0.46 
(+1.37) 1.4x10-3 0.15 N4bp3 (51.5 Mb) 15.7 PFC 
9230009I02Rik 
 
 11:50.89 
-0.94 
(-1.92) 1.6x10-3 0.16 
Agxt2l2,D11Ertd497e, 
Col23a1,Hnrpab,Lyrm7, 
G3bp1,Clk4,Damts2, 
Gria1,Zfp354a (51-57 Mb) 17-66 NCTX 
Ubash3b 
ubiquitin associated and SH3 
domain containing, B 9:40.82 
-0.61  
(-1.54) 1.7x10-3 0.17 Zfp2 (50.7 Mb) 14.9 HC 
Ablim2 actin-binding LIM protein 2 5:36.10 
0.21  
(+1.16) 2.4x10-3 0.20 Olfr54 (36.2 Mb) 14 Str 
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